» Articles » PMID: 39941714

The Role of Macrophages in Various Types of Tumors and the Possibility of Their Use As Targets for Antitumor Therapy

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2025 Feb 13
PMID 39941714
Authors
Affiliations
Soon will be listed here.
Abstract

In solid tumors, tumor-associated macrophages (TAMs) are one of the most numerous populations and play an important role in the processes of tumor cell invasion, metastasis, and angiogenesis. Therefore, TAMs are considered promising diagnostic and prognostic biomarkers of tumors, and many attempts have been made to influence these cells as part of antitumor therapy. There are several key principles of action on ТАМs: the inhibition of monocyte/macrophage transition; the destruction of macrophages; the reprogramming of macrophage phenotypes (polarization of M2 macrophages to M1); the stimulation of phagocytic activity of macrophages and CAR-M therapy. Despite the large number of studies in this area, to date, there are no adequate approaches using antitumor therapy based on alterations in TAM functioning that would show high efficacy when administered in a mono-regimen for the treatment of malignant neoplasms. Studies devoted to the evaluation of the efficacy of drugs acting on TAMs are characterized by a small sample and the large heterogeneity of patient groups; in addition, in such studies, chemotherapy or immunotherapy is used, which significantly complicates the evaluation of the effectiveness of the agent acting on TAMs. In this review, we attempted to systematize the evidence on attempts to influence TAMs in malignancies such as lung cancer, breast cancer, colorectal cancer, cervical cancer, prostate cancer, gastric cancer, head and neck squamous cell cancer, and soft tissue sarcomas.

References
1.
Benner B, Good L, Quiroga D, Schultz T, Kassem M, Carson W . Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. Drug Des Devel Ther. 2020; 14:1693-1704. PMC: 7210448. DOI: 10.2147/DDDT.S253232. View

2.
Kang J, Chen J, Lee C, Chang J, Shieh Y . Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol. 2010; 102(3):242-8. DOI: 10.1002/jso.21617. View

3.
Xu H, Xu B . Breast cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2024; 35(6):565-583. PMC: 10774137. DOI: 10.21147/j.issn.1000-9604.2023.06.02. View

4.
Gao J, Liang Y, Wang L . Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Front Immunol. 2022; 13:888713. PMC: 9280632. DOI: 10.3389/fimmu.2022.888713. View

5.
Ferrandina G, Lauriola L, Distefano M, Zannoni G, Gessi M, Legge F . Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol. 2002; 20(4):973-81. DOI: 10.1200/JCO.2002.20.4.973. View